Thursday, June 01, 2017 6:35:25 PM
By Rachel Graf
Law360, New York (June 1, 2017, 4:24 PM EDT) -- Medical technologies manufacturer C.R. Bard Inc. has unlawfully tied its popular tip location systems to its peripherally inserted central catheters in order to drive sales of its own PICCs at the expense of competitors, according to a suit filed by AngioDynamics Inc. Tuesday in New York federal court.
AngioDynamics said Bard only sells the stylet needed to use its tip location systems preloaded in its PICCs, violating antitrust laws and hurting sales of AngioDynamics’ own BioFlo PICCs that purportedly use superior technology to reduce blood clots. The tip location systems help doctors correctly position PICCs in patients.
“Even though AngioDynamics’ groundbreaking BioFlo PICCs significantly reduce thrombus accumulation and the reflux of blood, and are thus technologically far superior to Bard’s PICCs, Bard’s anti-competitive conduct has allowed it to capture and maintain a dominant position in the PICC market, exceeding 70 percent market share,” AngioDynamics said in the filing.
AngioDynamics’ BioFlo PICCs use Endexo Technology that reduces blood clots and consequently diminishes the likelihood of blood clotting events such as deep vein thrombosis and pulmonary embolism, according to the complaint.
Bard has been unable to create a PICC that can effectively reduce blood clots, but its tip location systems are very popular and make up more than 70 percent of the market, AngioDynamics claims.
Bard has leveraged this dominance in the tip location systems market to block PICC competition by tying the two products together, negatively impacting PICC price competition and making it difficult for AngioDynamics to grow its business, the filing said.
“We strongly deny the allegations raised by AngioDynamics in their complaint,” Scott Lowry, Bard vice president and treasurer, said in an emailed statement. “Clinicians select Bard products based on the clinical and economic benefits they provide to patients and health care providers. We intend to vigorously defend those claims.”
Bard’s decision to tie its tip location systems to its PICCs is motivated by purely competitive rather than technological reasons, the complaint claims. AngioDynamics notes that Bard did in fact receive FDA approval to sell its stylet separately from its PICCs, but has sold the stylet separately only to the Cleveland Clinic, which was then able to pair Bard’s tip location system with AngioDynamics’ BioFlo PICCs.
AngioDynamics is alleging violation of the Sherman Act and is seeking damages, an injunction, and attorneys’ fees and costs.
"This case involves a classic violation of the antitrust laws. Bard has no justification for preventing purchasers from choosing to use its market-leading tip location systems with AngioDynamics' innovative BioFlo PICCs," Philip J. Iovieno of Boies Schiller Flexner, counsel for AngioDynamics, said in a statement.
AngioDynamics is represented by Philip J. Iovieno, Adam R. Shaw, Anne M. Nardacci, Jenna C. Smith and Nicholas A. Gravante Jr. of Boies Schiller Flexner LLP.
Counsel information for Bard was not available Thursday.
The suit is AngioDynamics Inc. vs. C.R. Bard Inc., Bard Access Systems, Inc., case number 1:17-cv-00598 in the U.S. District Court for the Northern District of New York.
--Editing by Philip Shea.
Recent ANGO News
- US Index Futures Rise, Oil Dips Slightly • IH Market News • 04/04/2024 11:31:45 AM
- AngioDynamics Reports Fiscal Year 2024 Third Quarter Financial Results; Updates Fiscal Year 2024 Guidance to Reflect Asset Divestiture • Business Wire • 04/04/2024 11:00:00 AM
- AngioDynamics Receives 510(k) Clearance for AlphaVac F1885 System in Treatment of PE • Business Wire • 04/04/2024 10:45:00 AM
- AngioDynamics Announces Settlement of All Patent Litigation with C.R. Bard, Inc. • Business Wire • 04/01/2024 09:26:00 PM
- AngioDynamics to Report Fiscal 2024 Third Quarter Financial Results on April 4, 2024 • Business Wire • 03/19/2024 08:01:00 PM
- AngioDynamics to Participate in a Fireside Chat at the Oppenheimer Virtual Healthcare MedTech & Services Conference • Business Wire • 03/06/2024 09:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 01:49:30 AM
- AngioDynamics Announces Sale of PICC and Midline Product Portfolios to Spectrum Vascular for $45 Million • Business Wire • 02/15/2024 09:05:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/23/2024 09:14:00 PM
- AngioDynamics Announces FDA 510(k) Clearance of Auryon XL Radial Access Catheter to Treat Peripheral Arterial Disease • Business Wire • 01/23/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/22/2024 12:30:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/11/2024 12:30:19 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 01/08/2024 09:47:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/05/2024 12:15:29 PM
- AngioDynamics Reports Fiscal Year 2024 Second Quarter Financial Results; Revises Fiscal Year 2024 Guidance • Business Wire • 01/05/2024 12:00:00 PM
- AngioDynamics to Present at the J.P. Morgan Healthcare Conference • Business Wire • 12/21/2023 09:01:00 PM
- AngioDynamics to Report Fiscal 2024 Second Quarter Financial Results on January 5, 2024 • Business Wire • 12/07/2023 09:01:00 PM
- AngioDynamics Completes Patient Enrollment in APEX-AV Study Assessing AlphaVac F1885 System in Treatment of Pulmonary Embolism • Business Wire • 12/07/2023 01:00:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 11/07/2023 01:03:44 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 10/05/2023 09:15:12 PM
- Wednesday’s Wall Street Highlights: Apple, Intel, Cal-Maine, A10 Networks, and more • IH Market News • 10/04/2023 11:22:09 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/04/2023 11:15:31 AM
- AngioDynamics Reports Fiscal Year 2024 First Quarter Financial Results; Reaffirms Fiscal Year 2024 Guidance • Business Wire • 10/04/2023 11:00:00 AM
- Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] • Edgar (US Regulatory) • 09/22/2023 01:28:56 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM